###### Strengths and limitations of this study

-   The large sample size facilitated a robust conclusion.

-   Subgroup analysis was performed to investigate the interaction between disease severity and platelet-to-lymphocyte ratio.

-   Preintensive care unit data were not available in this database, which may lead to bias.

-   Patients with septic shock could not be identified in this database.

Introduction {#s1}
============

Sepsis is a major cause of morbidity and mortality worldwide, and it results from a dysregulation of the systemic inflammatory response to infection.[@R1] Despite significant advances in the pathophysiology and therapeutic strategies for sepsis, the mortality remains high,[@R3] at 300 deaths per 100 000 people.[@R4] An extremely complex systemic expression of inflammatory and anti-inflammatory response plays a critical role in the pathophysiological process of sepsis, which is strongly associated with an increased risk of mortality.[@R5] Identifying patients who are at a high risk of poor outcomes, in the early stage of sepsis, is vital for timely and adequate intervention.[@R6] While a significant amount of effort has been put into investigating promising biomarkers, the challenge of identifying these at-risk patients remains.[@R7]

In recent years, studies have reported that platelets and lymphocytes play critical roles in the inflammatory process. Therefore, the platelet-to-lymphocyte ratio (PLR)---a novel inflammatory factor---has received research attention recently, as it may act as an indicator of inflammation[@R8] in a wide spectrum of diseases, such as myocardial infarction,[@R9] acute kidney injury (AKI),[@R10] hepatocellular carcinoma[@R11] and non-small cell lung cancer.[@R12]

Based on the findings of previous studies, it is reasonable to speculate the presence of a potential relationship between PLR and mortality for sepsis. However, no investigation has been conducted. Therefore, in this study, we aimed to investigate the prognostic value of PLR for sepsis.

Materials and methods {#s2}
=====================

Database introduction {#s2a}
---------------------

This database included more than 58 000 patients who were admitted to the intensive care unit (ICU) of the Beth Israel Deaconess Medical Center from 2001 to 2008.[@R13] YS obtained access to this database (certification number: 1564657) and was responsible for data extraction.

Inclusion and exclusion criteria {#s2b}
--------------------------------

Adult patients meeting the criteria for sepsis were initially screened. The definition of sepsis was adapted from the recommendation in the Surviving Sepsis Campaign 2016.[@R14] Accordingly, sepsis was defined as the presence of a Sequential Organ Failure Assessment (SOFA) score ≥2 within 24 hours after ICU admission, accompanied by at least one infection site. The following criteria were used to exclude patients from this analysis: (1) age lower than 18 years; (2) having spent less than 48 hours in the ICU; and (3) absence of data on the serum platelet and lymphocyte counts within 24 hours after ICU admission. For patients who were admitted to the ICU more than once, only the first ICU stay was considered in this study.

Data extraction {#s2c}
---------------

Data on the demographic characteristics, laboratory outcomes, infection sites, vasopressor use and disease severity score were extracted from the database. Only patients with data on the serum platelet and lymphocyte counts within the first 24 hours after ICU admission were included. The first blood sample after ICU admission was used to calculate the PLR, which was defined as the ratio of the absolute platelet count and absolute lymphocyte count. Septic shock was considered as a special subgroup of sepsis. However, it was difficult to identify patients with septic shock in this database due to a lack of relevant information. Thus, data on vasopressor use were extracted for the subgroup analysis. Vasopressor use was defined as the use of any vasopressor agent, including norepinephrine, epinephrine, dobutamine, dopamine or vasopressin, within 48 hours after ICU admission.

Outcome definition {#s2d}
------------------

The primary endpoint was hospital mortality, which was defined as death during hospitalisation. The presence of AKI was defined according to the Creatinine-based Kidney Disease Improving Global Outcome criteria without urine output.[@R15] A 1.5-fold increase in the serum creatinine (SCr) level during the ICU stay, relative to the level at the baseline, was considered as the presence of AKI. In the present cohort, data on the baseline SCr values were missing in 20.3% of the cases. As AKI was not the primary outcome, we used a reported estimation equation [@R17] (reported median absolute error was 0.1--0.2 mg/dL) to calculate the missing values for patients without previous SCr data: SCr=0.74--0.2 (if female)+0.08 (if black)+0.0039 \* age (in years).

Management of missing data {#s2e}
--------------------------

Variables with missing data are common in the MIMIC III database, as it comprises more than 58 000 admissions. The percentage of missing values of serum lactate and albumin was 12.9% and 26.3%, respectively. For serum lactate, the crude comparison within three PLR levels is presented in [table 1](#T1){ref-type="table"} but was not included in the logistic models. The serum albumin was completely excluded from this study. For the rest of the variables included in the current study, the percentage of missing values was less than 5%. For normal distribution variables, such as age and fluid balance, we replaced the missing values with their mean values; for non-normal distribution parameters, missing values were replaced by the respective median, instead of using the multiple imputation technique. For dichotomous variables with less than 5% of missing values, the missing values were not filled.

###### 

Comparison of baseline characteristics within three PLR levels

  ---------------------------------------------------------------------------------------------------------------
  Variable                                     PLR ≤150\          150\<PLR≤250\      PLR \>250\         P value
                                               (n=1780)           (n=1380)           (n=2377)           
  -------------------------------------------- ------------------ ------------------ ------------------ ---------
   Age (years)                                 63.0±16.6          65.0±16.6          66.1±15.5          \<0.001

   Gender (male), n (%)                        805 (45.2)         590 (42.7)         1096 (46.1)        0.133

   BMI (kg/m^2^)                               30.8±8.9           34.1±13.5          35.2±39.5          0.001

  Ethnicity, n (%)                                                                                      

   White                                       1202 (67.5)        987 (71.5)         1761 (74.0)        0.754

   Black                                       180 (10.1)         101 (7.3)          146 (6.1)          \<0.001

   Asian                                       39 (2.2)           30 (2.1)           71 (2.9)           0.169

   Emergency                                   1641 (92.1)        1284 (93.0)        2229 (93.7)        0.138

  ICU type, n (%)                                                                                       

   MICU                                        953 (53.5)         727 (52.6)         1362 (57.2)        0.008

   CCU/CSRU                                    413 (23.2)         323 (23.4)         453 (19.0)         0.001

   TSICU/SICU                                  414 (23.2)         330 (23.9)         562 (23.6)         0.908

  Vasopressors, n (%)                                                                                   

   Norepinephrine                              566 (31.7)         374 (27.1)         711 (29.9)         0.016

   Dopamine                                    198 (11.1)         151 (10.9)         256 (10.7)         0.013

   Epinephrine                                 67 (3.7)           28 (2.0)           37 (1.5)           \<0.001

   Vasopressin                                 156 (8.7)          88 (6.3)           172 (7.2)          0.033

   Overall vasopressor use                     701 (39.3)         482 (34.9)         858 (36.1)         0.022

  Fluid input/output (mL/kg/48 hours)                                                                   

   Fluid intake                                99.9±60.9          90.7±57.6          97.2±61.2          \<0.001

   Urine output                                42.0±32.0          42.9±30.3          41.9±29.5          0.5659

   Fluid balance                               46.7±59.4          38.3±55.1          46.0±60.4          \<0.001

  Infection site, n (%)                                                                                 

   Respiratory infection                       1048 (58.8)        929 (67.3)         1580 (66.4)        \<0.001

   Blood infection                             768 (43.1)         509 (36.8)         998 (41.9)         0.001

   Urinary infection                           549 (30.8)         409 (29.6)         682 (28.6)         0.323

   Abdominal infection                         245 (13.7)         159 (11.5)         334 (14.0)         0.072

   Cerebral infection                          153 (8.5)          106 (7.6)          169 (7.1)          0.206

  Disease severity scores                                                                               

   SOFA on ICU admission median (IQR)          6 (4--9)           5 (4--8)           5 (3--7)           \<0.001

   Maximum SOFA during ICU stay median (IQR)   10 (7--14)         9 (7--12)          9 (7--12)          \<0.001

  Laboratory outcomes                                                                                   

   Maximum serum creatinine (mg/L)             2.5±2.7            2.2±2.1            2.1±1.9            \<0.001

   Minimum haemoglobin level (g/dL)            8.3±1.7            8.69±1.7           8.4±1.6            \<0.001

   Maximum serum sodium (mmol/L)               145.1±5.4          145.0±5.2          144.6±5.1          0.009

   Maximum serum lactate (mmol/L)              4.1±3.8 (n=1536)   3.4±3.1 (n=1174)   3.1±3.0 (n=2112)   \<0.001

   Platelet count (10^9^/L)                    146.7±88.0         225.1±107.2        197.5±163.4        \<0.001

   Lymphocyte count (10^9^/L)                  2.1±5.7            1.1±0.5            0.68±0.4           \<0.001

   PLR                                         91.8±37.1          195.8±28.6         557.5±484.8        \<0.001

  Clinical outcomes                                                                                     

   ICU LOS                                     9.9±10.1           9.3±8.7            10.1±9.9           0.071

   Hospital LOS                                17.7±15.1          16.6±13.5          17.2±13.7          0.082

   AKI, n (%)                                  861 (48.3)         601 (43.5)         1080 (45.4)        0.022

   Hospital mortality, n (%)                   475 (26.6)         291 (21.0)         621 (26.1)         \<0.001
  ---------------------------------------------------------------------------------------------------------------

AKI, acute kidney injury; BMI body mass index; CCU, coronary care unit; CSRU, cardiac surgery care unit; ICU, intensive care unit; LOS length of stay; MICU, multiple intensive care unit; PLR, platelet-to-lymphocyte ratio; SICU, surgical intensive care unit; SOFA, Sequential Organ Failure Assessment; TSICU, traumatic surgical intensive care unit

Patient and public involvement {#s2f}
------------------------------

No patient was involved in any part of this study.

Statistical analysis {#s2g}
--------------------

Continuous variables were expressed as mean±SD or median (IQR), as appropriate. A Student's t-test, analysis of variance, Wilcoxon rank-sum test or Kruskal-Wallis test was used, as appropriate. Categorical data were expressed as proportions and compared using the χ^2^ test. A knot of PLR (at a level of around 200) was detected using the Lowess smoother technique; thus, the linear spline function was initially used in the multivariate logistic regression. Thereafter, all the patients were further divided into three levels: those with a PLR ≤150 (level 1), 150\<PLR≤250 (level 2) and PLR \>250 (level 3). Variables including demographic characteristics, infection sites, disease severity score and laboratory measures potentially associated with mortality or those that had a p value \<0.20 in the univariate analyses were included in the multivariate logistic regression analyses.[@R18] An extended model approach was used for covariate adjustment: model 1=adjusted for age, admitted ICU type; model 2=model 1+(fluid balance at 48 hours after ICU admission); model 3=model 2+(infection sites); and model 4=model 3+(maximum SOFA score during the ICU stay). As we detected a U-shaped association between PLR and mortality, we did not introduce interaction items (such as PLR multiply other variables) in the logistic models. Instead, subgroup analyses were performed, according to the presence of AKI and vasopressor use and the median SOFA score. Multicollinearity was tested using the variance inflation factor (VIF) method, with a VIF ≥5 indicating the presence of multicollinearity. All the logistic regression models underwent a goodness of fit test. A two-tailed test was performed, and p\<0.05 was considered statistically significant. All statistical analyses were performed using STATA V.11.2.

Results {#s3}
=======

Baseline characteristics {#s3a}
------------------------

Data on a total of 5537 sepsis patients were included in this analysis. The overall mortality observed was 25.1%. Data on the comparisons of the baseline characteristics between the three PLR levels are listed in [table 1](#T1){ref-type="table"}. The mean age at admission was 64.9 years, and 44.9% of the participants were men. The rate of vasopressor use (701/1780 vs 482/1380, p=0.01) and a maximum SOFA score (10 (7--14) vs 9 (7--12), p\<0.001) were significantly higher in PLR level 1 than level 2; the presence of these variables was *non-significant* in level 3. The mortality was significantly higher among those in level 1 (475/1780 vs 291/1380, p\<0.001) and level 3 (621/2377 vs 291/1380, p=0.001).

Association between PLR and hospital mortality {#s3b}
----------------------------------------------

The PLR was initially used as a continuous variable in the logistic model, using linear spline function, as shown in [table 2](#T2){ref-type="table"}. We observed that, for PLRs ≤200, the OR of mortality was *non-significant* (OR 0.997; 95% CI 1.19 to 1.67), while the OR for PLRs \>200 was significant (OR 1.0002; 95% CI 1.0001 to 1.0004), after adjustment for covariates including the SOFA score, with a mean VIF of 2.89. The crude association between hospital mortality and PLR was also presented in online [supplementary figure S1](#SP1){ref-type="supplementary-material"}. In the extended multiple logistic regression analysis ([table 3](#T3){ref-type="table"}), both low and high PLR levels were significantly associated with increased hospital mortality, in model 1 (OR 1.41; 95% CI 1.19 to 1.67 and OR 1.28; 95% CI 1.09 to 1.51, respectively), model 2 (OR 1.34; 95% CI 1.13 to 1.59 and OR 1.23; 95% CI 1.05 to 1.45, respectively) and model 3 (OR 1.35; 95% CI 1.14 to 1.61 and OR 1.21; 95% CI 1.03 to 1.43, respectively). However, after adjustment for the maximum SOFA score in model 4, the OR for low PLR levels became *non-significant* (OR 1.15; 95% CI 0.96 to 1.38, p=0.123), while that for high PLR levels remained significant (OR 1.29; 95% CI 1.09 to 1.53, p=0.003), with a mean VIF of 2.53. The ORs of the covariates in model 4 are listed in online [supplementary table S1](#SP1){ref-type="supplementary-material"}.
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###### 

Multivariable logistic regressions of PLR using linear spline function

  Variables                         Crude OR   95**%** CI         P value   Adjusted OR   95**%** CI         P value
  --------------------------------- ---------- ------------------ --------- ------------- ------------------ ---------
  PLR (≤200)                        0.997      0.996 to 0.998     \<0.001   0.9993        0.9980 to 1.0006   0.319
  PLR (\>200)                       1.0002     1.0001 to 1.0004   0.001     1.0002        1.0000 to 1.0003   0.025
  Age (\>65 years)                  1.77       1.56 to 2.11       \<0.001   2.32          1.99 to 2.64       \<0.001
  Maximum SOFA                      1.20       1.18 to 1.22       \<0.001   1.18          1.16 to 1.20       \<0.001
  Urinary infection                 0.66       0.57 to 0.76       \<0.001   0.65          0.56 to 0.76       \<0.001
  Respiratory infection             1.29       1.13 to 1.47       \<0.001   1.25          1.09 to 1.45       0.002
  Blood infection                   2.14       1.89 to 2.42       \<0.001   1.49          1.29 to 1.71       \<0.001
   Fluid balance (mL/kg/48 hours)   1.006      1.005 to 1.007     \<0.001   1.002         1.0008 to 1.0031   0.001
  MICU                              1.34       1.15 to 1.56       \<0.001   1.15          0.97 to 1.37       0.089
  CCU/CSRU                          1.22       1.01 to 1.47       0.032     1.03          0.84 to 1.26       0.752

The mean variance inflation factor was 2.89, and p value of goodness of fit was 0.632.

CCU, coronary care unit; CSRU, cardiac surgery care unit; MICU, multiple intensive care unit; PLR, platelet-to-lymphocyte ratio; SOFA, Sequential Organ Failure Assessment.

###### 

Association between three PLR levels and hospital mortality

            PLR ≤150                        150\<PLR≤250             PLR \>250             
  --------- --------------------- --------- -------------- --------- --------------------- ---------
            OR (95% CI)           P value   OR (95% CI)    P value   OR (95% CI)           P value
  Model 1   1.41 (1.19 to 1.67)   \<0.001   Ref.           --        1.28 (1.09 to 1.51)   0.002
  Model 2   1.34 (1.13 to 1.59)   0.001     Ref.           --        1.23 (1.05 to 1.45)   0.009
  Model 3   1.35 (1.14 to 1.61)   0.001     Ref.           --        1.21 (1.03 to 1.43)   0.018
  Model 4   1.15 (0.96 to 1.38)   0.123     Ref.           --        1.29 (1.09 to 1.53)   0.003

Adjusted covariates: model 1=age, admitted ICU type. Model 2=model 1+(fluid balance at 48 hours after ICU admission). Model 3=model 2+(infection sites). Model 4=model 3+(maximum SOFA score during ICU stay).

The mean variance inflation factor was 2.53, and p value of goodness of fit was 0.665 for model 4.

ICU, intensive care unit; PLR, platelet-to-lymphocyte ratio; Ref reference category; SOFA, Sequential Organ Failure Assessment.

Subgroup analysis {#s3c}
-----------------

As the association between PLR and mortality was largely confounded by the SOFA score ([table 3](#T3){ref-type="table"}), we suspected that there was an interaction effect between disease severity and PLR level. Thus, we performed a subgroup analysis according to the existence of vasopressor use and AKI, and the median SOFA score (\>10 points), as shown in [figure 1](#F1){ref-type="fig"}. Unlike previous findings, the association between high PLRs and mortality became *non-significant* in the subgroups with vasopressor use (OR 1.20; 95% CI 0.95 to 1.53), AKI (OR 1.07; 95% CI 0.85 to 1.36) and a SOFA score \>10 (OR 1.14; 95% CI 0.90 to 1.44) and remained significant in the subgroups without vasopressor use (OR 1.39; 95% CI 1.08 to 1.77) and AKI (OR 1.54; 95% CI 1.20 to 1.99), and with a SOFA score ≤10 (OR 1.51; 95% CI 1.17 to 1.94). In the case of lower PLRs, the OR of mortality was *non-significant* in all the subgroups, after adjustment, except for the subgroup with AKI. Data on the comparisons of the characteristics between these subgroups are listed in online [supplementary table S2](#SP1){ref-type="supplementary-material"}. Finally, all the potential risk factors associated with in-hospital mortality were listed in online [supplementary table S3](#SP1){ref-type="supplementary-material"}.

![The crude and adjusted ORs in the subgroup analysis. PLR level 2 was used as the reference level in all the logistic models. AKI, acute kidney injury; PLR, platelet-to-lymphocyte ratio; SOFA, Sequential Organ Failure Assessment.](bmjopen-2018-022896f01){#F1}

Discussion {#s4}
==========

In this study, we observed a crude U-shaped association between the PLR and hospital mortality in patients with sepsis. However, after adjustment for the disease severity score, only high PLRs remained significantly associated with increased mortality; the association with low PLRs became *non-significant*. Furthermore, in the subgroup analysis, a significant association between high PLRs and mortality only existed in the subgroups without vasopressor use and AKI, or those with a SOFA score ≤10.

Growing evidence indicates that immune dysregulation (especially cellular immunity), including proinflammatory or anti-inflammatory responses during different stages, is common in cases of sepsis.[@R20] Recently, studies have reported that platelets play an important role in both the immunomodulatory and inflammatory process,[@R21] by inducing the release of inflammatory cytokines[@R23] and interacting with different kinds of bacteria and immune cells, including neutrophils, T-lymphocytes, natural killer (NK) cells and macrophages, which contribute to the initiation or exacerbation of the inflammatory process.[@R24] Low lymphocyte counts, which to a certain degree represent a suppressed immune and inflammatory response,[@R25] have also been reported to be associated with inflammatory diseases, such as cardiovascular disease[@R27] and type 2 diabetes.[@R28]

Based on these findings, the PLR was suggested as being a novel systematic inflammatory indicator,[@R29] and its use was initially reported in the prognostic prediction of neoplastic disorders, such as hepatocellular carcinoma and breast cancer. Accumulating evidence suggests that elevated PLRs are strongly associated with increased systemic inflammation, which may contribute to the progression and prognoses of many disorders, such as atherosclerosis[@R30] and diabetes mellitus.[@R31]

In contrast to our findings, Zheng *et al* [@R10] reported that both high and low PLRs are associated with increased mortality, among critically ill patients with AKI, after adjustment for the disease severity score in the Cox proportional hazards models. In that study, unlike in ours, a significant association was also observed in patients with vasopressin use. Several factors may contribute to this inconsistency between the findings, such as the use of different cohorts, PLR knots and definitions of vasopressor use. It is worth noting that, as the association between PLRs and outcomes varies greatly between different cohorts, the interheterogeneity within critically ill patients may also lead to a biased conclusion.

Akbas *et al* indicated that a high PLR was positively associated with increased epicardial adipose tissue deposition in diabetes patients[@R32]; this may be caused by higher inflammation rates. Wang *et al* [@R33] reviewed 134 patients with lung adenosquamous cancer and reported that high PLRs (\>150) were independently associated with shorter disease-free days and lower overall survival rates. Another study,[@R34] including 270 patients with hepatocellular carcinoma, found that elevated PLRs (above 220) were predictors of poor prognoses, while low PLRs (\<248.0) were associated with a lower tumour, node and metastasis stage, and low surgery incidence, in 695 patients with lung cancer.[@R35] Despite the fact that the study cohorts used in those studies were quite different from those used in ours, the reported PLR knots were quite similar to ours. However, the small sample sizes in those studies limited the statistical power for further stratification and subgroup analysis of low PLR. In the current study, we noticed that high PLRs (\>250) were associated with increased hospital mortality. As higher platelet levels, to a certain extent, are *prognostic* of inflammation of a higher severity and low lymphocyte counts may represent a suppressed immune and inflammatory response,[@R25] an increase in the PLR may reflect the degree of the inflammatory and immune response to the infection, which is related to a poor prognosis.

We also detected a *non-significant* association between low PLRs and mortality, in the case of sepsis. The association between low PLRs and outcomes was also reported in several studies. In a retrospective study[@R36] including 899 cases of laryngeal cancer, patients were divided into three PLR categories (low (≤119.55), moderate (\>119.55 and ≤193.55) and high (\>193.55)), and only patients with high PLRs experienced poor outcomes, including malnutrition and more advanced cancer stage; the association between outcomes and PLR levels were *non-significant* for those with low PLRs. Despite the cohort of that study being different from ours, the conclusion was consistent with that of our study. In the case of sepsis, a low platelet count is potentially associated with poor outcomes. In a large study including 931 patients with sepsis, Claushuis *et al* reported that patients with a low platelet count at ICU admission had a higher disease severity score and increased mortality risk.[@R37] Furthermore, thrombocytopenia---one of the most common hemostatic disorders in the case of sepsis---which is related with platelet consumption, was also associated with higher mortality.[@R38] However, in the present study, a significant association between low PLR and mortality was not detected. Further studies are needed to validate this conclusion.

Furthermore, according to the subgroup analysis, the association between high PLR and mortality became *non-significant* in the subgroups with vasopressor use, AKI or a SOFA score \>10; this association remained significant in the other subgroups. This finding further supported our speculation that there may be an interaction between PLR and disease severity. To the best of our knowledge, ours is the first study to report this interaction. However, the underlying mechanism of this interaction remains largely unknown. A critical characteristic of sepsis is fluid resuscitation and, in the current study, patients with vasopressor use, AKI or a SOFA score \>10, to a certain degree, represented patients with inflammation of a higher severity, and they may have a stronger need for fluid resuscitation. We also noticed that the fluid balance within 48 hours after ICU admission was significantly larger in these subgroups. It needs to be further investigated if fluid resuscitation affects the *prognostic* value of the PLR.

One of the strengths of our study is the large sample size, which enabled us to adjust for confounding factors and perform subgroup analyses. However, there are also several limitations to our study. First, the MIMIC III database comprises data on patients from 2001; since then, the guidelines for sepsis have changed significantly. The most recent definition of Sepsis 3.0 was used in the current study, and this may have introduced selection bias despite the fact that most of the basic interventions (use of fluids, vasopressors and antimicrobial agents) remained the same. Furthermore, as a decrease in the platelet count was a part of the SOFA score, using the definition of Sepsis 3.0, to a certain degree, may lead to a relatively low mean platelet count and potential multicollinearity. This bias cannot be fully avoided. However, the potential multicollinearity was verified in all the logistic models. Second, the platelet count can be affected by many cofounders, such as kinds of malignancies, immunological factors and kinds of drugs. However, due to the nature of retrospective study, these situations cannot be identified in this database. In addition, in the logistic model using PLR as a continuous variable ([table 2](#T2){ref-type="table"}), the OR was relatively small, despite the wide PLR range. Caution is therefore needed when interpreting these findings. Third, septic shock is a special subgroup of sepsis. However, patients with septic shock could not be distinguished in this study. Thus, patients were divided into subgroups, according to the existence of vasopressor use, AKI or a SOFA score \>10 which, to a certain extent, indicates the presence of an inflammatory response of a higher severity. Fourth, one of the main hypotheses of our study was the interaction effect between disease severity and PLR; yet, this interaction term was not introduced in the logistic model due to the U-shaped association between PLR and mortality. Further prospective studies are needed to verify our hypothesis. Finally, as high PLRs are associated with poor outcomes in various disorders, while low PLRs are not, it is not clear if interventions aimed at changing the PLR value may improve outcomes.

Conclusion {#s5}
==========

In patients with sepsis, a high PLR was significantly associated with poor survival, while the association was *non-significant* for those with a low PLR. However, the former association became *non-significant* in patients with more severe conditions, including those with vasopressor use, AKI or a SOFA score \>10. Future studies are needed to verify our hypothesis.
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